Carubbi Francesco, Alunno Alessia, Cipriani Paola, Bistoni Onelia, Scipioni Rosa, Liakouli Valiki, Ruscitti Piero, Berardicurti Onorina, Di Bartolomeo Salvatore, Gerli Roberto, Giacomelli Roberto
Rheumatology Unit, Department of Biotechnological and Applied Clinical Science, School of Medicine, University of L'Aquila, L'Aquila, AQ, Italy.
Department of Medicine, ASL1 Avezzano-Sulmona-L'Aquila, L'Aquila, AQ, Italy.
Curr Rheumatol Rev. 2019;15(1):27-43. doi: 10.2174/1573397114666180320113603.
Current patient care in rheumatology relies primarily on a combination of traditional clinical assessment and standard laboratory tests. Investigators seek to discover new biomarkers and novel technologies to boost the research in this field. Mechanistic biomarkers such as cytokines, cell types, antibodies, signaling molecules, are rooted in the mechanism underlying the disease and can guide the clinical management of the disease. Conversely, descriptive biomarkers are byproducts of the disease process, depict the state of a disease but are not involved in its pathogenesis. In this article, we reviewed the field of common laboratory biomarkers in rheumatology, highlighting both their descriptive or mechanistic value as well as their role in clinical practice.
目前风湿病的患者护理主要依赖于传统临床评估和标准实验室检查的结合。研究人员试图发现新的生物标志物和新技术，以推动该领域的研究。细胞因子、细胞类型、抗体、信号分子等机制性生物标志物源于疾病的潜在机制，可指导疾病的临床管理。相反，描述性生物标志物是疾病过程的副产品，描绘疾病状态但不参与其发病机制。在本文中，我们综述了风湿病常见实验室生物标志物领域，强调了它们的描述性或机制性价值以及在临床实践中的作用。
